CSL Seqirus

  1. Home
  2.  / 
  3. Partners & Products
  4.  / 
  5. Financial
  6.  / 
  7. CSL Seqirus

Who Is CSL Seqirus?

CSL Seqirus is a trusted partner for businesses in the field of flu vaccine administration, and their platform, flu360®, serves as a comprehensive solution to support flu vaccination businesses throughout the year.

With flu360, CSL Seqirus aims to make the process of administering flu vaccines as effortless as possible. They offer year-round flu campaign coverage, ensuring that businesses have the necessary support to successfully carry out their flu vaccination programs.

Through their flu360 platform, CSL Seqirus is committed to supporting businesses involved in flu vaccine administration. By offering year-round flu campaign coverage and a range of solutions that address clinical, financial, and operational aspects, flu360 aims to make the business of flu vaccine administration easier and more efficient for their partners.

Please let us know if you would like to learn more about Seqirus and we will have a representative reach out.

Where is CSL Seqirus Located?

CSL Seqirus’ U.S. Headquarters is located in Holly Springs, North Carolina, USA.

What Year was CSL Seqirus Founded?

CSL Seqirus was founded in 1916.

Who is CSL Seqirus Owned By?

CSL Behring’s parent company, CSL Limited, is headquartered in Melbourne, Victoria, Australia.

Who is on the CSL Seqirus Leadership Team?

Paul McKenzie is Chief Executive Officer and Managing Director of CSL Seqirus.

What is CSL Seqirus Famous For?

CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since their start in 1916, they have been driven by their promise to save lives using the latest technologies.

What Flu Vaccine Products Does CSL Seqirus Have Available Today?

CSL Seqirus offers the following influenza vaccines:


The first-and-only adjuvanted quadrivalent seasonal influenza vaccine approved for patients 65+ years.


The first-and-only cell-based flu vaccine approved for the prevention of influenza in patients 6+ months.

AFLURIA® QUADRIVALENT (Influenza Vaccine) 6+months

A quadrivalent influenza vaccine for the prevention of seasonal influenza in patients 6+ months.

What Are The Benefits of Using the CSL Seqirus flu360 Platform?

One key aspect of flu360 is its focus on providing comprehensive support across various areas of the flu vaccination business.

CSL Seqirus offers flu360 Solutions, which encompass clinical support, financial guidance, and operational efficiency.

Clinical Support

In terms of clinical support, flu360 provides resources that streamline and strengthen immunization clinics throughout the year, going beyond just the flu shot ingredients. This ensures that businesses have the necessary tools and knowledge to run efficient and effective immunization clinics.

Financial Guidance

Additionally, flu360 offers financial guidance, simplifying the process of ordering, coding, billing, and reimbursements, allowing businesses to prioritize their patients and influenza vaccinations without delays.

Operational Efficiency

Furthermore, flu360 enhances operational efficiency by providing solutions to address day-to-day operational burdens and inventory management challenges, ultimately increasing overall efficiency and productivity for flu vaccination businesses.

CSL Seqirus Vaccines Ordering and Cost Savings With MPPG

Please let us know if you would like to learn more about Seqirus and we will have a representative reach out.

Receiving contracted discounts on Seqirus’s influenza vaccine may to be done through an MPPG membership. When establishing a direct purchase account with Seqirus at flu360.com, and placing orders for FLUAD®, FLUCELVAX® and AFLURIA®, please remember to notify Seqirus of your membership in Medical Practice Purchasing Group, MPPG.


Client Testimonials

"Our savings on our malpractice insurance alone were significant. I highly recommend MPPG."

Subscribe for Email Updates

  • This field is for validation purposes and should be left unchanged.

News Archives